Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572933 · ClinicalTrials.gov registry record · Phase 3
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
A Phase 3 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT03572933 is a Phase 3 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 101 participants.
The verdict
NCT03572933, a Phase 3 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.
Interventions
- DRUG Placebo
- DRUG ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2018-06-30 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03572933
The ClinicalTrials.gov registry entry for NCT03572933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03572933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03572933 about?
NCT03572933 is a clinical study titled "Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder". A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.
What is the current status of trial NCT03572933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2018-06-30. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT03572933?
The interventions under investigation include: Placebo (DRUG), ganaxolone (DRUG).
Who is sponsoring clinical trial NCT03572933?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.